These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28474829)

  • 1. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained?
    Bar-Yoseph H; Chowers Y
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1473-1474. PubMed ID: 28474829
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Felwick R; Cummings JRF
    Aliment Pharmacol Ther; 2017 May; 45(10):1370-1371. PubMed ID: 28417492
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained? Authors' reply.
    Strik AS; D'Haens GR
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1474-1475. PubMed ID: 28474830
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
    Stasi R; Amadori S
    Br J Haematol; 2002 Feb; 116(2):334-7. PubMed ID: 11841434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti tumor necrosis factor alpha antibody: infliximab].
    Arimitsu S; Ito H
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():329-32. PubMed ID: 23126112
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy.
    Shrim A; Koren G
    Can Fam Physician; 2005 May; 51(5):667-8. PubMed ID: 15934268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD.
    Steenholdt C; Brynskov J; Bendtzen K
    Aliment Pharmacol Ther; 2012 Sep; 36(5):499-500; author reply 501. PubMed ID: 22860616
    [No Abstract]   [Full Text] [Related]  

  • 11. Investigation of the functional characteristics of antibodies to therapeutic anti-human tumor necrosis factor alpha monoclonal antibody.
    Yucel A; Aral AL; Basturk B; Karakus R; Aybay C; Aybay C
    Immunol Lett; 2007 Aug; 111(2):84-91. PubMed ID: 17618693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
    Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.
    Karppinen J; Korhonen T; Malmivaara A; Paimela L; Kyllönen E; Lindgren KA; Rantanen P; Tervonen O; Niinimäki J; Seitsalo S; Hurri H
    Spine (Phila Pa 1976); 2003 Apr; 28(8):750-3; discussion 753-4. PubMed ID: 12698115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
    Mori S; Imamura F; Kiyofuji C; Sugimoto M
    Mod Rheumatol; 2006; 16(4):251-5. PubMed ID: 16906378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healing of anastomotic enterocutaneous fistulae due to Crohn's disease by anti-tNF-alpha antibodies.
    Cougard PA; Desjeux A; Berdah S; Ezzedine S; Barthet M; Grimaud JC
    Inflamm Bowel Dis; 2010 Oct; 16(10):1632-3. PubMed ID: 20629185
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.